// App-Quantinova.ai

889 : Efficacy and Safety of Dabigatran in the Treatment and Secondary Prophylaxis of Children with Venous Thromboembolism and Thrombophilia

Researchers

Presenter

  • Leonardo R. Brandao

Principal Investigators

  • Igor Tartakovsky

  • Manuela Albisetti

  • Lisa Bomgaars

  • Elizabeth Chalmers

  • Lesley Mitchell

  • Matteo Luciani

  • Paola Saracco

  • Judy Felgenhauer

  • Olga Lvova

  • Monika Simetzberger

  • Zhichao Sun

  • Ingrid Gergei

  • Martina Brueckmann

  • Jacqueline Halton

Medical Centers

  • Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada

  • Therapeutic Area Cardiovascular Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany

  • Hematology Department, University Children’s Hospital, Zürich, Switzerland

  • Department of Pediatrics, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX

  • Royal Hospital for Sick Children, Glasgow, United Kingdom

  • Pediatric Hematology/Oncology Department, Pediatric Hospital Bambino Gesù, Rome, Italy

  • University Hospital, City of Health and Science of Turin, and Pediatric Hematology, Queen Margaret’s Children's Hospital, Turin, Italy

  • Pediatric Hematology Oncology, Providence Sacred Heart Medical Center and Children's Hospital, Spokane, WA

  • Urals State Medical University, Yekaterinburg, Russian Federation

  • City Children’s Hospital #1,Saint-Petersburg,Russian Federation

  • Department of Clinical Development, Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria

  • Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

  • Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany

  • University of Ottawa, Children's Hospital of Eastern Ontario, Ontario, Ontario, Canada

Locations

  • Canada

  • Germany

  • Switzerland

  • United States

  • United Kingdom

  • Italy

  • Russia

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Heparin

  • Pradax

  • Heparin

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT01895777

  • NCT02197416

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved